A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy

Song Yao; Christine B Ambrosone; Raymond U Osarogiagbon; Gary R Morrow; Charles Kamen

doi:10.1016/j.trecan.2022.10.002

A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy

Trends Cancer. 2023 Jan;9(1):6-8. doi: 10.1016/j.trecan.2022.10.002. Epub 2022 Oct 22.

Authors

Song Yao¹, Christine B Ambrosone², Raymond U Osarogiagbon³, Gary R Morrow⁴, Charles Kamen⁵

Affiliations

¹ Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: [email protected].
² Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
³ Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA.
⁴ Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
⁵ Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: [email protected].

Abstract

The approval and wide uptake of immune checkpoint inhibitors (ICIs) in oncology practice raise the concerns of possibly worsened racial disparities in cancer treatment due to biological and psychosocial reasons. We propose a multilevel biopsychosocial model to understand the opportunities and challenges to racial disparities in the era of cancer immunotherapy.

A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding